Brind.

Firefly Neuroscience utilizes the Evoke platform for assessments, while the company is listed on Nasdaq and Evoke has received FDA 510(k) clearance.

Steady: 0 in the last 7 days Updated sep 25

The latest in this situation

  1. Firefly Neuroscience announced a partnership and achieved FDA clearance for its non-drug treatment.
  2. Firefly will introduce the FDA-cleared Monarch device to its network, which utilizes the Evoke platform for assessment.

How it started

3 reports, 2 independent, last reported Sep 25. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Firefly Neuroscience utilizes the Evoke platform for assessments, while the company is listed on Nasdaq and Evoke has received FDA 510(k) clearance.

Who's involved

What this event is mainly about
EvokeNasdaqFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Firefly will introduce the FDA-cleared Monarch device to its network, which utilizes the Evoke platform for assessment.Sub-event
  2. Firefly Neuroscience announced a partnership and achieved FDA clearance for its non-drug treatment.1 source
  3. Firefly Neuroscience leverages Evoke platform for assessments; company listed on Nasdaq and Evoke is FDA 510(k)-cleared.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story